Coronavirus (COVID-19)

Russia's Sputnik V vaccine 91,6% efficacy

Sputnik V, the Russian vaccine, first published its phase III results in an article in a world-wide medical journal, The Lancet.

Russia's Sputnik V vaccine  91,6% efficacy

The Lancet has published the Sputnik V vaccine results, which has passed an international comparative evaluation. The vaccine has proven efficacy of 91.6%. 

These data are based on a study of 19,866 volunteers who received two doses of Sputnik V vaccine or placebo at the final checkpoint that was carried out based on 78 confirmed cases of COVID-19. The efficacy of the vaccine for the elderly (60 years or older) was 91.8%. A supply of two doses per person is necessary.

On August 1, 2020, phase 1 and phase 2 clinical trials of the vaccine were supplemented. The results showed that all the volunteers withstood the tests well; there were no records of serious or unexpected side effects. The vaccine showed the formation of a high cellular and antibody immune response. There are no participants who have contracted the coronavirus after administration of the vaccine in the current trial.

High precision tests were performed for antibodies in the blood serum of the volunteers (including an analysis of antibodies that neutralize the coronavirus), as well as the ability of the immune cells of the participants to activate in response to the protein S of the "spines" Of the coronavirus, which shows the formation of an immune reaction, either antibody or cellular, in response to vaccination. These tests confirmed the high percentage of the efficacy of the vaccine.

Already on the list are several countries, such as India, Venezuela, and the United Arab Emirates, which have started clinical trials of the Sputnik V vaccine at the local level. On August 11, the vaccine received a registration certificate from the Ministry of Health. The emergency regulations adopted during the COVID-19 pandemic can be used to vaccinate the population in Russia. 

Results from phase III clinical trials have shown high efficacy, immunogenicity, and safety of the "Sputnik V" vaccine, even in elderly people. 

Sputnik V vaccine provides full protection against severe clinical cases of COVID-19. It guarantees a sustained humoral (production of antibodies, the first line of defense) and cellular (long-term protection) immune response. More than 98% of the vaccinated people developed a humoral immune response and a 100% cellular immune response in the results.

The results showed that the level of neutralizing antibodies to the virus in people given the Sputnik V vaccine was 1.3 to 1.5 times higher than in patients who recovered from COVID-19. For the elderly, the vaccine's efficacy was 91.8%, and it did not differ statistically from that of the group of people aged 18 to 60 years. The results of the vaccine show excellent safety parameters. Most adverse effects (94%) were mild and included flu-like symptoms, administration site reactions, headache, and asthenia.

An Independent Data Monitoring Committee confirmed that no serious adverse effects related to the vaccine were shown. There were no cases of severe allergy or anaphylactic shock. Sputnik V vaccine has been given to more than 2 million people around the world. More than 50 countries have requested to vaccinate more than 1.2 billion people with the "Sputnik V" vaccine.

In February 2021, vaccination with "Sputnik V" has started or is starting in the following countries: Algeria, Armenia, Bolivia, the UAE, Kazakhstan, Turkmenistan, Palestine, Paraguay, Hungary, Bosnian Serb Republic, Venezuela, and Iran.

BlueNetHospitals - Hospital Los Cabos

BlueNet Hospitals.